Finanzen von LeonaBio Inc (LONA)LONALeonaBio Inc

Evaluating the bottom line, LeonaBio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -431.39%, provide a clear picture of how effectively LONA converts its operational activities into shareholder value.

In the context of the broader market, LONA competes directly with industry leaders such as ELTX and IMMP. With a market capitalization of $72.26M, it holds a significant position in the sector. When comparing efficiency, LONA's gross margin of N/A stands against ELTX's N/A and IMMP's 100.00%. Such benchmarking helps identify whether LeonaBio Inc is trading at a premium or discount relative to its financial performance.

LeonaBio has reported significant losses, with a GAAP EPS of -$24.70 for FY 2025 and a current ratio of 7.01, indicating good short-term liquidity despite ongoing losses.